|Mr. Timothy M. Mayleben M.B.A.||Pres, CEO & Director||1.16M||324.53k||1961|
|Mr. Richard B. Bartram||CFO & Corp. Sec.||429.25k||1.12M||1982|
|Mr. Mark A. Glickman||Chief Commercial Officer||629.14k||N/A||1966|
|Mr. Alexander Duke Schwartz||Sr. Director of Investor Relations||N/A||N/A||N/A|
|Ms. Regina Gore Cavaliere||Chief Ethics & Compliance Officer||N/A||N/A||N/A|
Esperion Therapeutics, Inc., a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination tablet, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was founded in 2008 and is headquartered in Ann Arbor, Michigan.
Esperion Therapeutics, Inc.’s ISS Governance QualityScore as of July 29, 2019 is 9. The pillar scores are Audit: 2; Board: 9; Shareholder Rights: 8; Compensation: 9.